AS-OCT, IVCM find and track epithelial downgrowth after penetrating keratoplasty

Article

Non-invasive imaging modalities, such as high-resolution anterior-segment optical coherence tomography (AS-OCT) and in-vivo confocal microscopy (IVCM) imaging, may be more sensitive to identifying and monitoring epithelial downgrowth, compared with routine light biomicroscopy in patients undergoing penetrating keratoplasty, and will perhaps replace more invasive diagnostics in these patients.

Non-invasive imaging modalities, such as high-resolution anterior-segment optical coherence tomography (AS-OCT) and in-vivo confocal microscopy (IVCM) imaging, may be more sensitive to identifying and monitoring epithelial downgrowth, compared with routine light biomicroscopy in patients undergoing penetrating keratoplasty, and will perhaps replace more invasive diagnostics in these patients, according to a recent case review retrospective study published in the November issue of Cornea.

Michael C. Chen, MD, of the University of California, Davis, and fellow researchers, conducted a retrospective case review on two eyes in two patients who had a history of multiple penetrating keratoplasties that developed epithelial downgrowth 4 and 6 months after the most recent penetrating graft.

The first patient was a 48-year-old man with a history of Acanthamoeba keratitis, who developed epithelial downgrowth after undergoing two therapeutic grafts over a 1-year period. The second patient was a 40-year-old man with a history of a corneal laceration, complicated by fungal keratitis, who was diagnosed with epithelial downgrowth after undergoing three penetrating grafts, placement of a glaucoma drainage device, and pars plana vitrectomy over a 3-year period. In both cases, high-resolution AS-OCT imaging identified-at the level of the endothelium-a highly reflective layer and IVCM images revealed round hyperreflective nuclei consistent with epithelium.

To access this study, click here.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.